AI Summary
5 min readThe science and politics of the new mRNA flu vaccine
The FDA approved Moderna's new mRNA flu vaccine in August, but it's only available for people age 50 and over—the group studied in the clinical trial. Dr. Anna Durbin, vaccine researcher and director of the Center for Immunization Research at Johns Hopkins Bloomberg School of Public Health, explains that this year's mRNA flu vaccine contains the exact same strains as traditional flu vaccines. The reason is structural: the annual strain selection meeting happened in March, and the FDA hasn't yet adjusted its schedule to take advantage of mRNA's faster manufacturing timeline.
Why the faster technology isn't producing a better match yet
The core promise of mRNA flu vaccines is that they can be produced much more quickly than traditional egg-based or cell-based vaccines. Traditional vaccines require a long lead time for strain selection because manufacturing takes months. With mRNA, the timeline could be compressed significantly. But Durbin points out that speed of production alone isn't enough—the regulatory process for strain selection hasn't changed.
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
Never miss an episode of Science Friday
Get every new episode summarized in your inbox — free, ~5 minutes to read.
No spam. Unsubscribe anytime.
What you'll learn
- 1 The science and politics of the new mRNA flu vaccine
- 2 (00:00) **Episode Introduction** - Host Flora introduces the new Moderna mRNA flu vaccine approved by the FDA in August for people 50+, and frames the key questions about strain matching, side effects, and agency dysfunction.
- 3 (01:58) **Guest Introduction** - Dr. Anna Durbin, vaccine researcher at Johns Hopkins, joins to discuss the mRNA flu vaccine rollout.
- 4 (02:15) **Strain Matching: This Year's mRNA Vaccine** - Dr. Durbin explains that the mRNA vaccine contains the exact same strains as traditional vaccines because strain selection happened in March, before mRNA's speed advantage could be leveraged.
- 5 (03:47) **The Missed Opportunity: No Summer FDA Meeting** - Dr. Durbin reveals that committee members at the March meeting explicitly suggested holding an additional FDA meeting later in the year to take advantage of mRNA's speed.
- 6 (04:55) **Evaluating the New Vaccine This Season** - CDC and global influenza surveillance systems will track vaccine effectiveness as they do every year, but workforce reductions at CDC, FDA, and HHS are making this harder.
- 7 (06:11) **The ACIP Problem: No Insurance Coverage** - The CDC's Advisory Committee on Immunization Practices (ACIP) no longer exists after RFK dismissed part of the panel, meaning there's no official recommendation for how to use the mRNA flu vaccine.
+ Full timestamped outline available in the app
Show Notes
A new mRNA flu vaccine made by Moderna was approved by the FDA in August, and is currently available for people aged 50 and over. The promise of an mRNA vaccine for flu is that it can be spun up more quickly than a traditional vaccine, meaning it could better match the flu strain that’s circulating.
Is that what happened this year? How are the side effects? And how has dysfunction at the health agencies impacted rollout? Flora discusses these questions and more with vaccine researcher Anna Durbin.
Guest:
Dr. Anna Durbin is a vaccine researcher, professor of international health, and director of the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health.
Transcripts for each episode are available within 1-3 days at sciencefriday.com.
Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that’s keeping you up at night? Call us: 877-472-4374
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More from this podcast
Science Friday →